Navigation Links
Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance
Date:2/3/2009

mbursement coverage with non- contracted BCBS plans and continued growth in adoption of and reimbursement of its tests; the outcome, success or results of clinical trials; the applicability of clinical study results to actual outcomes; and the company's intention to conduct additional studies in DCIS and the timing of any such studies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the three-month period ended September 30, 2008. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.



                             Genomic Health, Inc.
               Condensed Consolidated Statements of Operations
             
'/>"/>
SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Enrichment of Genomic Loci for Targeted Sequencing Application Is Focus of 2009 AGBT Conference Workshop
2. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
3. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
4. Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum
5. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
6. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
7. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
8. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
9. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
10. Transgenomic Receives Accreditation From College of American Pathologists
11. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... SETAUKET, N.Y., May 25, 2011 John S. Kovach, ... Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert ... of Directors. Dr. Royds is Chair of ... a leading clinical research organization, which he founded in ...
... a Phase 2 multicenter, randomized, double-blind, proof-of-concept and ... 136) improved signs and symptoms of rheumatoid arthritis ... with methotrexate (MTX).  Findings from Part A of ... League Against Rheumatism (EULAR) Congress showed that a ...
... May 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... today jointly announced that Watson has acquired the ... for EUR 400 million ($562 million) in cash ... the acquisition, Watson gains a leading generic product ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 2Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 4Watson Acquires Specifar Pharmaceuticals 2Watson Acquires Specifar Pharmaceuticals 3Watson Acquires Specifar Pharmaceuticals 4Watson Acquires Specifar Pharmaceuticals 5Watson Acquires Specifar Pharmaceuticals 6
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing ... common stock at a price to the public of $6.00 ... 30-day option to purchase up to 1,250,000 additional shares of ... are expected to begin trading on the NYSE MKT on ... William Blair & Company, L.L.C. and JMP Securities LLC ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
Breaking Biology News(10 mins):Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... -- An Illinois research team has succeeded in ... that simultaneously reduces atmospheric carbon dioxide and produces ... engineering professor Paul Kenis and his research group ... startup company, to produce a catalyst that improves ...
... New Rochelle, NY, October 6, 2011Measurable changes in brain ... consequence of virus-induced injury during the early stages of ... implications in disease prognosis are detailed in an article ... Connectivity , a bimonthly peer-reviewed journal published by ...
... new research program funded by the National Institutes of ... has on human health. Led by NIH,s National Institute ... the risk factors that make people more vulnerable to ... such as air pollution and toxic chemicals; and the ...
Cached Biology News:Ionic liquid catalyst helps turn emissions into fuel 2Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? 2NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: